THE US Food and Drug Administration has approved Nerlynx (neratinib) for the "extended adjuvant treatment" of early-stage, HER2-positive breast cancer, meaning it can help lower the risk of the cancer returning.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jul 17